Protalix BioTherapeutics, Inc.
PLX · XNYSCIK 1006281fmd_0SFC1X80RXG85Y60XSEEENE0R5Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2009 to Sep 30, 2026, 67 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 9 | 21 | 34 | 55 | 63 | 38 | 48 | 65 | 53 | 53 |
| Cost of revenue | 8 | 15 | 9 | 11 | 11 | 16 | 20 | 23 | 24 | 27 |
| Gross profit | 1 | 4 | 25 | 44 | 52 | 22 | 28 | 43 | 29 | 26 |
| Research and development | 30 | 32 | 33 | 45 | 38 | 30 | 29 | 17 | 13 | 20 |
| Selling, general and administrative | 9 | 12 | 11 | 10 | 11 | 13 | 12 | 15 | 12 | 12 |
| Compensation and benefits | – | – | – | – | – | – | 19 | 24 | 22 | – |
| Operating income | (33) | (35) | (19) | (11) | 3 | (20) | (13) | 10 | 4 | (6) |
| Interest expense | – | – | – | – | – | – | – | – | – | – |
| Other non-operating income (expense) | 4 | (49) | (7) | (8) | (9) | (7) | (1) | (2) | 0 | (0) |
| Income before taxes | – | – | – | – | (7) | (28) | (14) | 9 | 4 | (6) |
| Income tax expense | – | – | – | – | – | – | 1 | 0 | 1 | 1 |
| Net income from continuing operations | (29) | (83) | (26) | (18) | – | – | (15) | 8 | 3 | (7) |
| Net income | (29) | (83) | (26) | (18) | (7) | (28) | (15) | 8 | 3 | (7) |
| Net income to common shareholders | – | – | – | – | – | (28) | (15) | 7 | 3 | (7) |